Introduction: AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe... Context: SARS-CoV-2 is a global public-health concern. Interventions to prevent infection are urgently needed. The anti-inflammatory and antiviral effects of neem... Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD),... Current treatment options offer only symptomatic pain relief for patients with osteoarthritis (OA). Thus, a need exists for effective treatment... In the event of a highly pathogenic influenza pandemic, the Indian subcontinent would need 1.2 billion doses of vaccine to... Rise of diphtheria cases in adults is a cause of concern worldwide. Pertussis is also now affecting adults. We assessed...
First-in-Human Study to Evaluate Safety, Tolerabil...
Neem (Azadirachta Indica A. Juss) Capsules for Pro...
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3...
Efficacy of an Ayurvedic Formulation for Mild-to-m...
A pandemic influenza vaccine in India: from strain...
Diphtheria, Tetanus, and Pertussis Immunity in Ind...
MIC is established to fill a gap in technical expertise and medical knowledge for transformative outcomes in clinical research for betterment of patients. As a ‘specialized’ service provider we provide a higher level of scientific engagement, medical expertise and value to our clients through thought leadership, deep domain knowledge, and a scientifically focus approach. Our focus has always been on partnering and working closely with each client to build scientifically robust concepts to achieve better outcomes, increase operational efficiencies and ensure consistent regulatory compliance.
MIC has created a cost and resource-optimized business model, affording them the flexibility and scalability to tap into a talent with a diverse skill-set. The firm is a service provider for the biotech generic pharmaceutical, medical device and contract research industry in the areas of clinical development, safety & risk management, regulatory affairs and scientific writing services.
".......wrote several clinical study reports for us and we would not hesitate to hire their services again. The work they produced was of high quality, delivered on time and they were easy to work with.”
Statistical analyses
Clinical Study Protocols
Clinical Study
Manuscripts
Publications
Conference Posters/abstracts
In the phase 3 PROpel trial, a significant improvement in overall survival is observed for olaparib with abiraterone compared to placebo with abiraterone in patients with mCRPC. The improvement observed was primarily attributabl...
In the phase 2 CAPRI trial, patients with recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR) deficient high-grade serous ovarian cancer (HGSOC) and clinically benefited from PARPi before progression, ...
In the KEYNOTE-B61 phase 2, single-arm study, patients with previously untreated stage IV non-clear-cell renal cell carcinoma treated with pembrolizumab plus lenvatinib showed a confirmed objective response (49%; 95% CI 41-57), in...
In single-arm, phase 2 RAGNAR study, treatment with erdafitinib (selective pan-FGFR tyrosine kinase inhibitor) showed clinical benefit in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR al...
In the Phase III study in 708 patients with HR–positive, HER2-negative advanced breast cancer who progressed during or after aromatase inhibitor therapy, the combination of AKT inhibitor capivasertib and fulvestrant showed sig...
In a phase 3 RUBY trial, dostarlimab combined with chemotherapy (carboplatin and paclitaxel) significantly increased progression-free survival as compared to placebo, with a substantial benefit in the dMMR–MSI-H population in pa...
In POSEIDON study, a treatment-naive patients with metastatic non-small cell lung cancer (NSCLC), tremelimumab (anti-CTLA-4 antibody) plus durvalumab (anti-PD-L1 antibody) and platinum-based chemotherapy demonstrated a statistical...
In this Phase III study (CHOICE-01), patients with treatment-naive, advanced NSCLC with EGFR/ALK mutations, treatment with toripalimab (a humanized IgG4K monoclonal antibody specific for human PD-1) in combination with chemotherap...
In patients with advanced NSCLC without EGFR, ALK, or ROS1 genomic tumor aberrations, treatment with cemiplimab plus chemotherapy showed a consistent relationship between ORR and baseline PD-L1 expression, with benefits versus che...
In patients with pretreated germline BRCA1/2 breast cancer who had received a median of two prior chemotherapy lines for advanced disease, treatment with Lurbinectedin (a selective inhibitor of oncogenic transcription) showed an O...
Indoleamine 2,3- dioxygenase 1 (IDO1) is a cytosolic heme-containing enzyme that functions to catalyze tryptophan (Trp) degradation and kynurenine (Kyn) production, and the Trp:Kyn ratio reflects IDO1 activity. Tobacco carcinogens...
In patients with advanced GIST who progressed on or were intolerant to first-line treatment with imatinib, ripretinib, a switch-control TKI, showed comparable median PFS as sunitinib, suggesting that ripretinib is active as second...
In 50 patients with advanced EGFR exon 20-mutant NSCLC, treatment with poziotinib showed confirmed ORRs of 31% by blinded independent review, with a median PFS of 5.5 months. Preclinical studies, in silico modeling, and molecular ...
In patients with recurrent mismatch repair proficient (MMRP) Endometrial Cancer, treatment with talazoparib and avelumab showed 11.4 % confirmed ORR and 22.9 % PFS at 6 months. Patients with homologous recombination repair (HRR) a...
In patients with previously untreated locally advanced or metastatic TNBC, the addition of pembrolizumab to chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine–carboplatin) resulted in significantly longer overall survival ...
Brentuximab vedotin plus standard chemotherapy (B+AVD group) showed a 6-year OS of 93.9% compared to standard chemotherapy (ABVD group) 89.4% in patients with previously untreated, stage III/ IV HL. Fewer patients in the B+AVD gro...
The addition of capivasertib to fulvestrant showed a significant PFS benefit in the original pathway-altered and non-altered subgroups. In the pathway altered subgroup, the median OS with the combination was significantly longer t...
In patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy and checkpoint inhibitor therapy, adagrasib showed an objective response of 42.9%. Tumor shrinkage of any magnitude was observed in 79.5% ...
In chemotherapy-naïve, PD-L1-positive (tumour proportion score ≥1%) patients with locally advanced or metastatic NSCLC, tiragolumab plus atezolizumab showed a significant improvement in both objective response rate (ORR) and p...
n patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction therapy, Ivosidenib/Azacitidine combination showed significantly longer EFS compared to Azacitidine at a median follow-up of 12.4 months...
In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared w...
Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in...
In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio R...
In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months...
Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI...
The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showe...
In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio R...
Participants who received a booster at least 5 months after a second dose of Covid-19 vaccine had 90% lower mortality due to Covid-19 than participants who did not receive a booster. The adjusted hazard ratio for death due to Covi...
Multiple non-JAK inhibitor-based therapies are being explored in pre-clinical and clinical settings for the treatment of myelofibrosis, targeting outside of the JAK-STAT pathway. (Ref: Tremblay D et al. Cells. 2021) #oncologyresea...
Check point inhibitors, such as anti- programmed death 1 (PD-1) (Nivolumab, Pembrolizumab)/ anti-programmed death-ligand 1 (PD-L1) therapies (Atezolizumab, Avelumab and Durvalumab) have dramatically changed the therapeutic and pro...
Accelerated approval to Polivy (Polatuzumab vedotin), in combination with the chemotherapy bendamustine and rituximab (P-BR) by the U.S. FDA for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (...
Recommendations of an Oncology Drugs Advisory Committee (ODAC) against approval of Quizartinib further opened debate on effective end point for registration studies of acute myeloid leukemia (AML). Though, the Study AC220-007 show...
Eboigbodin K.E. et al., Diagnostic Microbiology and Infectious Disease, 2016 Recent worldwide large outbursts of the ZIKV necessitate the availability of a rapid, cost-effective and quick diagnostic method for ZIKV detection. Conv...
Salje H. et al., PNAS, 2016 Contraction of the disease during an infectious disease epidemic is dependent on interrelated factors, that may be directly related to the individual (age, sex), his family or the wider community of whi...
Lebel C. et al., Biological Psychiatry, 2016 It is well- known that perinatal maternal depression is a serious health concern, with its negative effects lasting on children. Prenatal depression is associated with altered br...
Marso S.P. et al., NEJM 2016 In order to fulfil regulatory requirement of establishing cardiovascular safety of new diabetes therapies in patients with type 2 diabetes a non inferiority trial as compared to placebo was plan...
Zhang P. et al., 2017, The Lancet Utidelone, a genetically engineered epothilone analogue, has emerged as a potential treatment for breast cancer in phase 1 and 2 trials. This phase III multicentre, open- label, randomized ...
Pradeep A. R. et al, November 2016, Journal of Periodontology Gingivitis, the early stage of periodontal disease, is an infection of the tissues that surround your teeth, and is caused by a buildup of plaque.Anant...
Pradeep A. R. et al, November 2016, Journal of Periodontology Since the discovery of antibiotics in the 1940s, research in this domain has been continuous, giving the world of an array of antibiotics. However, developm...
Ling L. et al, 2015, Nature Since the discovery of antibiotics in the 1940s, research in this domain has been continuous, giving the world of an array of antibiotics. However, development of resistance to these antibiotics ...
Mosquirix(RTS,S/ AS01) is a protein- based recombinant malaria vaccine, recently approved by the EMA. It is the first licensed vaccine, to be used for a parasitic disease. Developed by GlaxoSmithKline Vaccines, Belgium, in ...
Thabit H. et al., Lancet Diabetes Endocrinology, 2017 An open- label, parallel- group, randomized controlled trial was conducted by Thabit H et al. to assess the safety and efficacy of fully closed-loop insulin d...
